Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization ...

The research led by Ottawa's Dr. Guy Trudel is one of four new Canadian studies to be conducted aboard the International ...

Q3 2025 Earnings Call Transcript November 3, 2025 Karyopharm Therapeutics Inc. misses on earnings expectations. Reported EPS ...

A 56-year-old man was admitted to the hospital because of left lower abdominal pain and anemia. He had a 1-year history of ...

In the U.S., Vafseo® (vadadustat) is approved for the treatment of anemia due to CKD in adults who have been receiving dialysis for at least three months. Nephrologists in the U.S. began prescribing ...

Minimal residual disease (MRD)-guided retreatment with anti-CD20 antibodies effectively lowers MRD levels and delays clinical relapse in patients with high-risk chronic lymphocytic leukemia (CLL), ...

Shares of Akebia Therapeutics fell sharply premarket after it abandoned plans for a clinical trial of its anemia treatment in patients not on kidney dialysis following a meeting with the Food and Drug ...

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ...

Progress has been made in identifying and treating the disease, but the impact of federal cuts is yet to be borne out.

Modus Therapeutics Holding AB (publ) ("Modus" or the "Company") announces that the competent authorities in Italy have approved the Company's dose selection for its ...